论文部分内容阅读
目的观察静脉蔗糖铁(氢氧化铁蔗糖复合物)联合促红细胞生成素(EPO)治疗肾性贫血的有效性和安全性。方法选择50例住院患者,根据公式计算总补铁量,应用蔗糖铁进行补铁治疗,同时联合EPO皮下注射治疗,于用药前及用药后4周检测血红蛋白(Hb)、红细胞压积(HCT)、红细胞(RBC)、网织红细胞(Ret)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)等指标,同时观察有无不良反应。结果 50例患者中铁贮存低下者16例(40%),相对铁缺乏者24例(60%);用药后4周与用药前相比Hb、HCT、RBC、Ret、SF及TSAT显著升高,差异有统计学意义(P<0.05);50例中显效35例,有效13例,进步2例,总有效率95%,无效0例,无不良反应发生。结论静脉予以蔗糖铁联合EPO治疗尿毒症铁缺乏患者贫血,疗效确切、方便可行、起效较快,无明确不良反应发生。
Objective To observe the efficacy and safety of intravenous iron sucrose (iron hydroxide sucrose complex) combined with erythropoietin (EPO) in the treatment of renal anemia. Methods Fifty inpatients were enrolled in this study. Total iron supplementation was calculated according to the formula. Iron supplementation was performed with sucrose iron and subcutaneously injected with EPO. Hemoglobin (Hb) and hematocrit (HCT) were measured before and 4 weeks after treatment. , RBC, Ret, SF, TSAT and other indicators were observed, with or without adverse reactions. Results Among the 50 patients, there were 16 (40%) patients with low iron stores and 24 (60%) patients with iron deficiency. The levels of Hb, HCT, RBC, Ret, SF and TSAT were significantly increased 4 weeks after treatment compared with those before treatment The difference was statistically significant (P <0.05); 50 cases markedly effective in 35 cases, effective in 13 cases, improved in 2 cases, the total effective rate was 95%, 0 cases, no adverse reactions. Conclusion Intravenous administration of sucrose and iron combined with EPO in the treatment of anemia in uremic patients with iron deficiency deficiency has definite curative effect, convenient and feasible, rapid onset and no definite adverse reactions.